STK26 and colorectal cancer: While minor quantitative differences existed between clones “#1” and “#2”, potentially reflecting CRISPR editing heterogeneity, compensatory adaptation, or stochastic single-cell effects, both exhibited unequivocal suppression of oncogenic phenotypes, establishing STK26 as a key regulator of colorectal cancer progression.